> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Janssen’s Tremfya Ok’d for Active Psoriatic Arthritis
- URL: https://www.fdaweb.com/janssens-tremfya-okd-for-active-psoriatic-arthritis/
- Published: 2020-07-15T12:00:00.000Z
- Updated: 2026-09-14T16:21:11.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147208

FDA has approved a Janssen Pharmaceutical Companies supplemental BLA for tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA). The drug was approved in 2017 for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Janssen says Tremfya is the first treatment approved for active PsA that selectively inhibits interleukin (IL)-23, a “naturally occurring cytokine that is involved in normal inflammatory and immune responses associated with the symptoms of PsA.” Approval was based on results from two pivotal Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2, which evaluated Tremfya’s subcutaneous injection in adults with active PsA compared to placebo. Data showed that at 24 weeks, 52% and 64% of patients achieving an ACR20 response, a common arthritis endpoint, compared to 22% and 33% in patients treated with placebo in DISCOVER-1 and DISCOVER-2, respectively.